Last reviewed · How we verify
mFOLFOX6 adjuvant chemotherapy
mFOLFOX6 is a combination chemotherapy regimen that targets rapidly dividing cancer cells.
mFOLFOX6 is a combination chemotherapy regimen that targets rapidly dividing cancer cells. Used for Adjuvant treatment of stage III colon cancer.
At a glance
| Generic name | mFOLFOX6 adjuvant chemotherapy |
|---|---|
| Also known as | Oxaliplatin, Leucovorin, 5-Fluorouracil |
| Sponsor | Sun Yat-sen University |
| Drug class | Platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It combines oxaliplatin, 5-fluorouracil, and leucovorin to inhibit DNA synthesis and function, leading to cell death in cancer cells. This regimen is used in the treatment of colorectal cancer.
Approved indications
- Adjuvant treatment of stage III colon cancer
Common side effects
- Diarrhea
- Nausea and vomiting
- Fatigue
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (PHASE2, PHASE3)
- Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression (PHASE2)
- Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer (PHASE2)
- Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis (NA)
- COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer (EARLY_PHASE1)
- Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer (NA)
- IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting (PHASE3)
- A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mFOLFOX6 adjuvant chemotherapy CI brief — competitive landscape report
- mFOLFOX6 adjuvant chemotherapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI